CHICAGO, May 27, 2024 /PRNewswire/ -- Preclinical Imaging Market in terms of revenue was estimated to be worth $946 million in 2024 and is poised to reach $1,259 million by 2029, growing at a CAGR of 5.9% from 2024 to 2029 according to a new report by MarketsandMarkets.
The growth in the preclinical imaging market is driven by the increasing funding to support preclinical research, development of low-cost & affordable preclinical imaging systems, and increasing market demand for new drug development and non-invasive small-animal imaging techniques.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841
Browse in-depth TOC on "Preclinical Imaging Market"
83 - Tables
40 - Figures
165 - Pages
Preclinical Imaging Market Scope:
Report Coverage | Details |
Market Revenue in 2024 | $946 million |
Estimated Value by 2029 | $1,259 million |
Growth Rate | Poised to grow at a CAGR of 5.9% |
Market Size Available for | 2018-2029 |
Forecast Period | 2024-2029 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Product Type, Application, End User, and Region |
Geographies Covered | North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, And Rest of Latin America), and Middle East & Africa (GCC Countries, and Rest of MEA) |
Report Highlights | Updated financial information / product portfolio of players |
Key Market Opportunities | Increasing Adoption of Imaging Systems for Preclinical Purposes |
Key Market Drivers | Increasing market demand for non-invasive small animal imaging techniques |
Optical Imaging reagents segment is the largest product type of the preclinical reagents market in 2023.
Based on reagents, the preclinical imaging market is segmented into optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. Among these, optical imaging reagents segment accounted for the largest share of the preclinical imaging market in 2023. The large market share of the optical imaging reagents segment is attributed to the high penetration of optical imaging modalities in preclinical research studies
Oncology segment is the largest application of the preclinical imaging market in 2023.
Based on application, the preclinical imaging market is segmented into oncology, cardiology, neurology, infectious diseases, immunology and inflammation, and other applications. In 2023, oncology segment accounted for the largest share of the market. This can be due to as oncology benefits greatly from advancements in molecular imaging, allowing researchers to target specific biomarkers associated with cancer cells. This provides valuable insights into tumour biology and drug targeting.
By end user, pharmaceutical & biotechnology companies are the largest end user in the brain preclinical imaging market in 2023.
Based on end user, the preclinical imaging market is segmented into pharmaceutical & biotechnology companies, academic and research centers, imaging centers, and other end users. In 2023, the pharmaceutical & biotechnology companies segment accounted for the largest share in the market. The volume of research and development work conducted by these companies has increased significantly, accompanied by a rise in investment for these activities. The ongoing need for advanced drugs will continue to drive demand for research and development efforts. Biotechnology companies utilize this technology extensively due to its wide range of applications.
North America dominates the global preclinical imaging market in 2023.
The preclinical imaging market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America is anticipated to dominate the preclinical imaging market due to its developed infrastructure, numerous preclinical projects, and higher adoption rates of advanced technological devices in the region.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=841
Preclinical Imaging Market Dynamics:
Drivers:
1. Increasing market demand for non-invasive small animal imaging techniques
Restraints:
1. Strict regulations governing preclinical research
Opportunities:
1. Increasing Adoption of Imaging Systems for Preclinical Purposes
Challenge:
1. Technological and procedural limitations associated with standalone preclinical imaging systems
Key Market Players of Preclinical Imaging Industry:
Prominent players in the preclinical imaging market include MR Solutions (UK), Mediso Ltd. (UK), Sofie (US), Fujifilm Visual Sonics (Canada), MILABS B.V. (Netherlands), Aspect Imaging Limited (US), Li-Cor Biosciences (US), ICONEUS (Paris), Advanced Molecular Vision (UK), Viewworks (Korea), Kub Technologies (US), Medikor (US), Trifoil Imaging (US), IVIM Technology Corp. (South Korea), Cubresa, Inc. (Canada), Berthold Technologies GMBH & CO.KG (Germany), Miltenyi Biotech GmbH (Germany), AI4R (France), Bruker Corporation (US), and Revvity, Inc. (US).
Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:
- By Supply Side: Tier 1 (25%), Tier 2 (5%), and Tier 3 (70%)
- By Designation: C-level Executives (27%), Director-level (18%), and Others (55%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East and Africa (5%)
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=841
Preclinical Imaging Market - Key Benefits of Buying the Report:
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
- Analysis of key drivers (technological advancements in the field of molecular imaging, increasing market demand for noninvasive small-animal imaging techniques, growing number of public-private initiatives and funding to support preclinical researches, and development of low-cost & affordable preclinical imaging systems), restraints (strict regulation, significant installation and operational cost ), opportunities (expansion in emerging markets, and increasing demand for non-invasive techniques) and challenge (Technological and procedural limitations associated with standalone preclinical imaging systems)
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the preclinical imaging market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of preclinical imaging solutions across regions.
- Market Diversification: Exhaustive information about solutions, untapped regions, recent developments, and investments in the preclinical imaging market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the preclinical imaging market.
Related Reports:
Mice Model Market - Global Forecasts to 2029
Contrast Media Market - Global Forecasts to 2029
Diagnostic Imaging Market - Global Forecasts to 2028
Clinical Trial Imaging Market - Global Forecasts to 2028
eClinical Solutions Market - Global Forecasts to 2027
Get access to the latest updates on Preclinical Imaging Companies and Preclinical Imaging Industry
About MarketsandMarkets:
MarketsandMarkets has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/preclinical-imaging-market-worth-1-259-million--marketsandmarkets-302155875.html
